Order Samples

Florastor Kids® & Florastor Baby

Daily oral probiotics formulated to support microbiome balance in children, including during periods of disruption.

The only pediatric probiotics with Saccharomyces boulardii CNCM I-745

  • More Clinical Studies Than Most Probiotics: S. boulardii CNCM I-745, is one of the most extensively studied probiotic strains in pediatric GI health, supported by multiple randomized controlled trials (RCTs) and meta-analyses.*
  • Less Antibiotic-Associated Diarrhea (AAD) Risk: Meta-analyses of pediatric RCTs demonstrate significant reductions in AAD and support digestive health during antibiotic use.8, 25
  • More Rapid Resolution: Meta-analysis demonstrated 1-day shorter duration of acute diarrhea in pediatric patients receiving Saccharomyces boulardii CNCM I-745 compared with control.8
  • Fewer Episodes of Diarrhea During Follow-up: In a controlled pediatric study, short-term supplementation was associated with fewer recurrent diarrhea episodes during the follow-up period.26
  • *Data on file; PubMed/Clinical Trials.gov searches April 2025
In pediatric acute diarrhea, meta-analysis data showed approximately 1 day shorter diarrhea duration versus control. Across included studies, the most commonly evaluated supplementation was 500 mg/day. Reduction in the mean duration (days) of diarrhea with S. boulardii. Shown is the lower and higher range of mean duration of diarrhea. Based on meta-analysis including 3,450 children aged 1 month to 15 years with acute diarrhea, compared to receiving Florastor + ORS vs placebo. S. boulardii significantly reduced the duration of diarrhea by ONE DAY compared to placebo Based on a meta-analysis of pediatric acute gastroenteritis studies evaluating Saccharomyces boulardii. (Szajewska, et al.).

In pediatric acute diarrhea, meta-analysis data showed approximately 1 day shorter diarrhea duration versus control. Across included studies, the most commonly evaluated supplementation was 500 mg/day.

Reduction in the mean duration (days) of diarrhea with S. boulardii. Shown is the lower and higher range of mean duration of diarrhea.

Based on meta-analysis including 3,450 children aged 1 month to 15 years with acute diarrhea, compared to receiving Florastor + ORS vs placebo.

  • S. boulardii significantly reduced the duration of diarrhea by ONE DAY compared to placebo

Based on a meta-analysis of pediatric acute gastroenteritis studies evaluating Saccharomyces boulardii. (Szajewska, et al.).

Reduction in the number of children with diarrhea 48 hours following supplementation with Saccharomyces boulardii CNCM I-745 compared with control, when used alongside standard rehydration therapy. Based on a RCT including 363 children aged 3 months to 5 years old.# Lower incidence of subsequent diarrhea episodes compared with control Including a relative risk reduction of 24% after the first 2 days of use

Reduction in the number of children with diarrhea 48 hours following supplementation with Saccharomyces boulardii CNCM I-745 compared with control, when used alongside standard rehydration therapy.

Based on a RCT including 363 children aged 3 months to 5 years old.#

  • Lower incidence of subsequent diarrhea episodes compared with control
  • Including a relative risk reduction of 24% after the first 2 days of use
Based on a RCT including 900 children aged 2 months to 12 years old with acute watery diarrhea.# Reduced stool frequency and shortened duration of diarrhea compared to control Supports recovery during the acute episode 50% Fewer New Diarrheal Episodes During 2-Month Follow-Up.

Based on a RCT including 900 children aged 2 months to 12 years old with acute watery diarrhea.#

  • Reduced stool frequency and shortened duration of diarrhea compared to control
  • Supports recovery during the acute episode
  • 50% Fewer New Diarrheal Episodes During 2-Month Follow-Up.

1 Sachet 250mg, twice daily with antibiotics Saccharomyces boulardii CNCM I-745 (250 mg twice daily during antibiotic therapy among 333 hospitalized children) reduced the risk of antibiotic-associated diarrhea by 78% versus antibiotics alone. Diarrhea outcomes were assessed through a 2-week follow-up period after antibiotic discontinuation. S. boulardii CNCM I-745 reduced the risk of AAD in children when used with antibiotics compared with antibiotics alone.

1 Sachet 250mg, twice daily with antibiotics

Saccharomyces boulardii CNCM I-745 (250 mg twice daily during antibiotic therapy among 333 hospitalized children) reduced the risk of antibiotic-associated diarrhea by 78% versus antibiotics alone. Diarrhea outcomes were assessed through a 2-week follow-up period after antibiotic discontinuation.

  • S. boulardii CNCM I-745 reduced the risk of AAD in children when used with antibiotics compared with antibiotics alone.
1 Sachet 250mg, twice daily 2 pediatric RCTs (N=2579) analyzed as a pediatric subgroup/meta-analysis, RR: 0.25, 95% CI: 0.08-0.73.8 In an RCT, S. boulardii CNCM I-745 added to antibiotic therapy reduced the risk of C. difficile-associated diarrhea in children compared with antibiotics alone.

1 Sachet 250mg, twice daily

2 pediatric RCTs (N=2579) analyzed as a pediatric subgroup/meta-analysis, RR: 0.25, 95% CI: 0.08-0.73.8

  • In an RCT, S. boulardii CNCM I-745 added to antibiotic therapy reduced the risk of C. difficile-associated diarrhea in children compared with antibiotics alone.
The Gut Microbiota and Immune System

The Gut Microbiota and Immune System

Benefits of Florastor (S. boulardii CNCM I-745)

Florastor Safety Warning

Do not use Florastor or other probiotics in any ICU setting and in those individuals with open arterial and venous access required (such as a Vascath, Permcath, or AV fistula).

Do not use for any individual with a central line or port or in the surroundings of any patient with a central line or port. [Central lines include short- and long-term central venous catheters (CVCs) and peripherally inserted central catheters (PICCs)].

Do not use Florastor for pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Do not use Florastor probiotics if allergic to any components (especially yeast). Less than 1% of patients experience constipation or thirst.

Very rarely, side effects such as: allergic reaction (skin rash). Fungemia or sepsis in patients with a central venous catheter, and in hospitalized, immunocompromised patients may occur.

For product questions or to report an adverse event, please call 877-356-7787.

This educational information is intended for use by qualified healthcare practitioners only and is not intended for use by consumers or to substitute for appropriate professional care.

Her Florastor Safety Warning

Clinical studies suggest daily use of L-theanine 200 mg for at least 28 days for optimal stress and anxiety relief. Safe daily use up to 400 mg/day for up to 8 weeks; safety beyond this period is not established. Periodic assessment is advised. L-theanine may interact with antihypertensives and CNS depressants, potentially enhancing effects. Monitor patients for hypotension or sedation. Safety of L-theanine and probiotics in pregnancy, lactation, and individuals under 18 is not well established. Use should be based on clinical judgment. L-theanine may cause mild adverse effects such as metallic taste or dry mouth, typically resolving upon discontinuation. L-theanine is generally non-sedating, but individual response should be assessed, especially when combined with sedatives or alcohol. Probiotics may interact with immune-suppressing drugs. Probiotics should not be used in pre-/post-organ or bone marrow transplant patients or those who are severely immunocompromised or critically ill. Do not use in acute-care settings, in patients with open arterial/venous access (e.g., Vascath, Permcath, AV fistula), or around those with central lines (CVCs, PICCs). Though rare, probiotic supplementation carries a theoretical risk in immunocompromised patients or those with serious underlying conditions. Do not use if allergic to any components. Keep out of reach of children.

For product questions or to report an adverse event, please call 877-356-7787.

This educational information is intended for use by qualified healthcare professionals only and is not intended for use by consumers or to substitute for appropriate professional care.

See References
  1. Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017 Jan 2;8(1):17-32. doi: 10.1080/19490976.2016.1267890. Epub 2016 Dec 14. PMID: 27973989; PMCID: PMC5341914.
  2. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, Teixeira MM, Nicoli JR. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009 Aug;191(8):623-30. doi: 10.1007/s00203-009-0491-x. Epub 2009 Jun 13. PMID: 19526225.
  3. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006 Apr;101(4):812-22. doi: 10.1111/j.1572-0241.2006.00465.x. PMID: 16635227.
  4. Neut C, Mahieux S, Dubreuil LJ. Antibiotic susceptibility of probiotic strains: Is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017 Nov;47(7):477-483. doi: 10.1016/j.medmal.2017.07.001. Epub 2017 Aug 7. PMID: 28797834.
  5. Shan LS et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with lower respiratory tract infections. Beneficial Microbes. 2013;4(4):329-334. doi:10.3920/BM2013.0008.
  6. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000 Oct;31(4):1012-7. doi: 10.1086/318130. Epub 2000 Oct 25. PMID: 11049785.
  7. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2015 Oct;42(7):793-801. doi: 10.1111/apt.13344. Epub 2015 Jul 27. PMID: 26216624.
  8. Szajewska H, Kołodziej M, Zalewski BM. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update. Aliment Pharmacol Ther. 2020 Apr;51(7):678-688. doi: 10.1111/apt.15659. Epub 2020 Feb 13. PMID: 32056266.
  9. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008 Aug;135(2):568-79. doi: 10.1053/j.gastro.2008.04.017. Epub 2008 Apr 18. PMID: 18570896.
  10. Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019 Oct;24(5):e12651. doi: 10.1111/hel.12651. Epub 2019 Aug 14. PMID: 31414551.
  11. Can M et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Medical Science Monitor. 2006;12(4):2004-2007.
  12. More MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - A review. Clinical and Experimental Gastroenterology. 2015;8:237-255. doi:10.2147/CEG.S85574.
  13. Seddik H et al. Saccharomyces boulardii CNCM I-745® plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. European Journal of Clinical Pharmacology. 2019;75(5):639-645. doi:10.1007/s00228-019-02625-0.
  14. McFarland, L. V. (2008). Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3, 563-578. doi: 10.2217/17460913.3.5.563
  15. Beaugerie, L., Flahault, A., Barbut, F., Atlan, P., Lalande, V., Cousin, P., et al. (2003). Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol. Ther. 17,905-912. doi:10.1046/j. 1365-2036.2003.01531.x
  16. Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., & De Meyer, R. (1986). Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20, 192-196.
  17. Czerucka D, Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World journal of gastroenterology. 2019;25(18):2188-2203. doi:10.3748/wjg.v25.i18.2188.
  18. Joly F et al. Saccharomyces boulardii CNCM I-745. In: Marteau P, Dore J, eds. Gut Microbiota: A Full-Fledged Organ. Paris: John Libbey Eurotext; 2017:305-350.
  19. Bertuccini L., Russo R., Iosi F., Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. International Journal of Immunopathology and Pharmacology 2017, Vol. 30(2) 163–167.
  20. Kimura K., Ozeki M., Juneja LR., Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007; 74(1):39-45.
  21. Coman MM., Egidi N., Silvi S., De Leone R., Verdenelli MC. Probiotic SYNBIO® Blend’s Impact on Constipation in Healthy Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Fermentation. 2024; 10(10):518. https://doi.org/10.3390/fermentation10100518.
  22. Yoto, A., Motoki, M., Murao, S. and Yokogoshi, H. (2012) Effects of L-Theanine or Caffeine Intake on Changes in Blood Pressure under Physical and Psychological Stresses. Journal of Physiological Anthropology, 31, 28. http://dx.doi.org/10.1186/1880-6805-31-28
  23. White DJ., de Klerk S., Woods W., Gondalia S., Noonan C., Scholey AB. Anti-Stress, Behavioural and Magnetoencephalography Effects of an L-Theanine-Based Nutrient Drink: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial. Nutrients. 2016 Jan 19;8(1):53. doi: 10.3390/nu8010053. PMID: 26797633; PMCID: PMC4728665.
  24. McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018 May 7; 5:124. doi: 10.3389/fmed.2018.00124. PMID: 29868585; PMCID: PMC5949321. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949321
  25. Szajewska H, Skórka A, Dyląg M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Alimentary Pharmacology & Therapeutics. 2007;25(3):257–264. https://pubmed.ncbi.nlm.nih.gov/17269987/
  26. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Saeed Shekhani M, Siddiqi AQ. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World Journal of Gastroenterology. 2006;12(28):4557-4560.
  27. Dinleyici EC, Kara A, Dalgic N, Kurugol Z, Arica V, Metin O, Temur E, Turel O, Guven S, Yasa O, Bulut S, Tanir G, Yazar AS, Karbuz A, Sancar M, Erguven M, Akca G, Eren M, Ozen M, Vandenplas Y. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. Benef Microbes. 2015;6(4):415-21. doi: 10.3920/BM2014.0086. Epub 2015 Feb 12. PMID: 25653151.https://pubmed.ncbi.nlm.nih.gov/25653151/
Welcome to the Florastor® site for Healthcare Professionals

Are you a health care professional?

No

By indicating that I am a Health Care Professional, I acknowledge: